Company Background

A New York corporation, founded in 1993, is engaged in studies of biomedical problems.The philosophy behind Bio Balance is that accurate descriptions of drug-receptor interactions will lead to the development of better pharmaceuticals. Bio Balance is devoted to a biophysical description of the initial receptor response. From this research, Bio Balance has developed the proprietary technology to prevent receptor desensitization, which is also known as tachyphylaxis, down-regulation, tolerance or fade. This should lead to improved pharmaceuticals and be an attractive and alternative route to drug development in the future

About the Founder

Richard G. Lanzara, Ph.D. -

Dr.Lanzara holds a Bachelor of Science degree in Chemistry (cum laude) from SUNY at Albany; a Master's degree in Public Health and Environmental Cellular Chemistry from the University of Michigan/School of Public Health and a Ph.D. in Biomedical Sciences and Pharmacology from the Mount Sinai School of Medicine.

For the past several years, he has been a member of the New York State Biotechnology Association and for more than twenty years, he has worked in academic and medical settings as Professor of Allied Health Sciences, CUNY. Additionally, he has been a member for many years in a number of scientific organizations including: The New York Academy of Sciences, The American Chemical Society, The American Society for Respiratory Care, and The American Association for the Advancement of Science.

For more than ten years, he has been and continues to be involved in receptor research. Previously, he has worked with Drs. Chin and Bernstein in the Department of Environmental and Industrial Health at the University of Michigan School of Public Health on tissue culture techniques with carcinogens and theories of carcinogenesis; Dr. Albert Keston (inventor of the test tape for detecting glucose) on mutarotase and staining techniques; Dr. Gordan, in the Department of Pathology at Mount Sinai, on autoradiography and electronmicroscopy; Dr. Kirchberger in the Department of Physiology and Biophysics at Mt. Sinai, on the purification and characterization of phospholamban; Drs. Liebman and Wilk in the Department of Pharmacology, Mt. Sinai School of Medicine, on the purification of pyroglutamyl peptidase II and molecular modeling studies of Thyrotropin Releasing Hormone (TRH) and various analogs with pyroglutamyl peptidase II; and Dr. Rubenstein in the Department of Physiology and Biophysics at Mt. Sinai, on the theoretical mechanisms of activation of G protein coupled receptors.